Candel Therapeutics heads into October with short sellers firmly entrenched, an activist on the register, and analysts who have just turned notably more constructive, a combination that sets up a pointed disagreement about where this development-stage biotech goes from here.
The short position is one of the more significant in small-cap biotech right now. Short interest has climbed to 22.4% of the free float, up about 6% over the past month, and the ORTEX short score has edged up to 79.1 this week, close to its highest reading of the past fortnight. Days to cover stand at just over 10, which means any sharp reversal in sentiment would face a crowded exit. The stock itself has reinforced the bears' hand over the period, falling 16.8% in the past month to $10.88. Against that, availability in the borrow market has actually loosened considerably this week: availability now runs at 81%, up from roughly 61% to 66% through most of September and compared to a 52-week low of just 0.5%. The cost to borrow has also dropped sharply, down 43% over the past month to under 1%. The message from the lending market is that fresh short supply has increased, making it cheaper and easier to put on new positions even as SI stays elevated.
Options sentiment, by contrast, is not particularly alarmed. The put/call ratio sits at 0.35, barely above its 20-day average of 0.34 and well inside the 52-week range of 0.08 to 0.79. There is no meaningful hedging premium building in the options market, which reads as a notable divergence from the elevated short book.
The Street is lined up squarely in the bull camp, which sits in direct tension with the short positioning. Nine analysts carry buy-equivalent ratings with no holds and no sells. The mean price target is $21.75, implying around 100% upside from the current price. The most recent action came from B of A Securities on September 21, where analyst Alec Stranahan upgraded the stock to Buy and raised his target from $12 to $18, a move that follows an August upgrade of the target from $9 to $12 after a positive earnings reaction. Stifel initiated coverage in July with a Buy and a $22 target. The bull case centres on Candel's two viral immunotherapy platforms and a multi-billion dollar potential market in prostate cancer, anchored by the CAN-2409 programme and a prospective BLA submission. The bear case is the standard development-stage binary: capital requirements, FDA timing risk, and dilution. Factor scores reflect the analyst optimism: analyst recommendation divergence ranks in the 92nd percentile, EPS surprise also ranks 92nd, and the 90-day EPS momentum score reaches the 97th percentile. The short score rank, however, sits at just the 4th percentile, flagging how heavily this stock is shorted relative to the broader universe.
The ownership picture adds another dimension. Paul Manning filed a Schedule 13D/A in March, which means there is a confirmed activist holder on the register at approximately 7.9% of the company. A 13D filing indicates stated active intent, not passive exposure, and Manning made his stake clear through a disclosed open-market purchase of 550,458 shares at $5.45 in February. That is a $3 million discretionary bet at roughly half the current price. The institutional register also shows BlackRock and State Street both adding meaningfully in recent periods, with BlackRock adding around 1.86 million shares and State Street adding 2.73 million shares as last reported through August. As always with 13D/G disclosures, stakes are as-last-disclosed around the 5% threshold and holders can fall below 5% without a further filing. On the insider side, the CEO Peter Paul Tak sold a combined $3.16 million worth of shares on September 10 and 11 under a pre-arranged 10b5-1 plan. Planned sales are a scheduled mechanism rather than a discretionary signal, but the volume is worth noting at a point when the stock has given back ground.
Earnings have consistently produced positive near-term price reactions. The four most recent prints all generated gains on day one, ranging from 1.3% to 9.7%, and five-day returns were stronger still, the most recent August 13 print produced a 15.6% five-day move. The next report is set for November 13, giving the short book roughly six weeks to either build further or face a catalyst that has historically moved the stock higher. The key catalyst is not the earnings number per se but any update on the CAN-2409 BLA submission timeline and manufacturing readiness, which the bear case identifies as the pivotal near-term uncertainty.
With the short book large but borrowing conditions loosening, and a newly upgraded analyst community pointing to targets roughly double the current price, the dominant question into November is whether the BLA process delivers the confirmation that analysts have already priced in.
See the live data behind this article on ORTEX.
Open CADL on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
